Kneller R
Department of Intellectual Property, Research Center for Advanced Science and Technology, University of Tokyo, Tokyo 153-8904, Japan.
Clin Cancer Res. 2001 Apr;7(4):761-74.
Why is technology transfer important for cancer and other biomedical researchers? What do biomedical researchers need to know about technology transfer? This report will address these questions in the context of the United States technology transfer system, which is now approximately 20 years old. To accomplish this goal, this report first summarizes the importance of technology transfer and the role of intellectual property rights. Then it describes the sequential steps in technology transfer from universities to industry. Next, it describes technology transfer from the NIH intramural laboratories and other federal laboratories to industry. Finally, it describes unique aspects of technology transfer involving clinical trials. URL citations to the latest federal guidelines and regulations governing technology transfer are provided. Where appropriate, comparisons will be made with technology transfer systems in other countries. I hope that this step-by-step description of the technology transfer process will enable cancer researchers to play a more proactive role in this process and thus increase the likelihood that their discoveries will be successfully commercialized. I also hope that this report will assist such researchers to understand the policy and institutional considerations that underlie current debates concerning technology transfer.
为什么技术转让对癌症及其他生物医学研究人员很重要?生物医学研究人员需要了解哪些关于技术转让的知识?本报告将在美国已有约20年历史的技术转让体系背景下探讨这些问题。为实现这一目标,本报告首先总结技术转让的重要性和知识产权的作用。接着描述从大学到产业的技术转让的一系列步骤。然后介绍从美国国立卫生研究院内部实验室及其他联邦实验室到产业的技术转让。最后,阐述涉及临床试验的技术转让的独特方面。提供了指向最新联邦技术转让指导方针和法规的网址引用。在适当的地方,将与其他国家的技术转让体系进行比较。我希望对技术转让过程的这一步骤式描述能使癌症研究人员在这一过程中发挥更积极主动的作用,从而增加他们的发现成功商业化的可能性。我还希望本报告能帮助这类研究人员理解当前关于技术转让辩论背后的政策和制度考量。